Instil Bio is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. Using its manufacturing process, Co. is developing its primary TIL product candidate, ITIL-168, for the treatment of melanoma. Co. is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor platform. The TIL stock yearly return is shown above.
The yearly return on the TIL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TIL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|